Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex

Molecular Endocrinology

Volumn 19, Issue 1, 2005, Pages 175-183

  McMahon, Lloyd P ^a   Yue, Wei ^a   Santen, Richard J ^a   Lawrence Jr , John C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CAFFEINE; CYCLOPHILIN; FARNESYLTHIOSALICYLIC ACID; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; RAS PROTEIN; WORTMANNIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; COMPLEX FORMATION; DISSOCIATION; EFFECTOR CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARRIER PROTEINS; CELL EXTRACTS; CELL LINE; FARNESOL; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEINS; SALICYLIC ACIDS;

MAMMALIA; RAPTORES;

EID: 11244264754     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0305     Document Type: Article

References (56)

1. Harris TE, Lawrence Jr JC 2003 TOR signaling. Sci STKE 2003:re15
2. Schmelzle T, Hall MN 2000 TOR, a central controller of cell growth. Cell 103:253-262
3. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence Jr JC, Abraham RT 1997 Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101
4. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM 1998 RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95:1432-1437
5. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat T, Tokunaga C, Avruch J, Yonezawa K 2002 Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-189
6. McMahon LP, Choi KM, Lin TA, Abraham RT, Lawrence JC 2002 The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 22:7428-7438
7. Gingras A-C, Raught B, Sonenberg N 1999 elF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Ann Rev Biochem 68:913-963
8. Lawrence Jr JC, Brunn GJ 2001 Insulin signaling and the control of PHAS-I phosphorylation. Prog Mol Subcell Biol 26:1-31
9. Kim D-H, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM 2002 mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-175
10. Kim DH, Sarbassov dos D, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM 2003 GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11:895-904
11. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN 2002 Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457-468
12. Choi KM, McMahon LP, Lawrence Jr JC 2003 Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J Biol Chem 276:19667-19673
13. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, Yonezawa K 2003 The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278:15461-15464
14. Abraham RT, Wiederrecht GJ 1996 Immunopharmacology of rapamycin. Ann Rev Immunol 14:483-510
15. Odorico JS, Sollinger HW 2002 Technical and immunosuppressive advances in transplantation for insulin-dependent diabetes mellitus. World J Surg 26:194-211
16. Garza L, Aude YW, Saucedo JF 2002 Can we prevent in-stent restenosis? Curr Opin Cardiol 17:518-525
17. Huang S, Houghton PJ 2003 Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3:371-377
18. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben Baruch G, Kloog Y 1998 Dislodgment and accelerated degradation of Ras. Biochemistry 37:1306-1314
19. Gana-Weisz M, Haklai R, Marciano D, Egozi Y, Ben Baruch G, Kloog Y 1997 The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Biochem Biophys Res Commun 239:900-904
20. Gingras A-C, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N 1999 Regulation of 4E-BP1 phosphorylation: a novel two step mechanism. Genes Dev 13:1422-1437
21. Yang D, Brunn GJ, Lawrence Jr JC 1999 Mutational analysis of sites in the translational regulator, PHAS-I, that are selectively phosphorylated by mTOR. FEBS Lett 453:387-390
22. Mothe-Satney I, Brunn GJ, McMahon LP, Capaldo CT, Abraham RT, Lawrence Jr JC 2000 Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem 275:33836-33843
23. Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D, Kloog Y 1998 Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta 1406:40-50
24. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC, Abraham RT 1996 Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15:5256-5267
25. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT 1999 Inhibition of ATM and ATR kinase activities by the radiosensitizing agent caffeine. Cancer Res 59:4375-4382
26. Law BK, Norgaard P, Gnudi L, Kahn BB, Poulson HS, Moses HL 1999 Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. J Biol Chem 274:4743-4748
27. Law BK, Norgaard P, Moses HL 2000 Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J Biol Chem 275:10796-10801
28. Casey PJ, Seabra MC 1996 Protein prenyltransferases. J Biol Chem 271:5289-5292
29. Yamagata K, Sanders LK, Kaufmann WE, Yee W, Barnes CA, Nathans D, Worley PF 1994 Rheb, a growth factor-regulated and synaptic activity-regulated gene, encodes a novel Ras-related protein. J Biol Chem 269:16333-16339
30. Zhang Y, Gao XS, Saucedo LJ, Ru BG, Edgar BA, Pan DJ 2003 Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578-581
31. Inoki K, Li Y, Xu T, Guan KL 2003 Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829-1834
32. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J 2003 Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13:1259-1268
33. Castro AF, Rebhun JF, Clark GJ, Quilliam LA 2003 Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 278:32493-32496
34. Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Norgaard P, Moses HL 2000 Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J Biol Chem 275:38261-38267
35. Jansen B, Heere-Ress E, Schlagbauer-Wadl H, Halaschek-Wiener J, Waltering S, Moll I, Pehamberger H, Marciano D, Kloog Y, Wolff K 1999 Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med 77:792-797
36. Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, Pehamberger H, Gana-Weisz M, Ben David E, Kloog Y, Wolff K 1999 Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 96:14019-14024
37. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben Baruch G, Marciano D, Gierschik P, Kloog Y 1999 A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18:2579-2588
38. Marom M, Haklai R, Ben Baruch G, Marciano D, Egozi Y, Kloog Y 1995 Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270:22263-22270
39. Beretta L, Gingras A-C, Svitkin YV, Hall MN, Sonenberg N 1996 Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 15:658-664
40. Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW 1994 Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci USA 91:11477-11481
41. Kerekatte V, Smiley K, Hu B, Smith A, Gelder F, De Benedetti A 1995 The proto-oncogene/translation factor elF4E: a survey of its expression in breast carcinomas. Int J Cancer 64:27-31
42. De Benedetti A, Rhoads RE 1990 Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl Acad Sci USA 87:8212-8216
43. Lazaris-Karatzas A, Montine KS, Sonenberg N 1990 Malignant transformation by a eukaryotic initiation factor subunit that binds mRNA 5′ cap. Nature 345:544-547
44. Zimmer SG, De Benedetti A, Graff JR 2000 Translational control of malignancy: the mRNA cap-binding protein, elF-4E, as a central regulator of tumor formation, growth, invasion, and metastasis. Anticancer Res 20:1343-1351
45. Kozak M 1991 An analysis of vertebrate mRNA sequences: initimations of translational control. J Cell Biol 115:887-903
46. Koromilas A, Lazaris-Karatzas A, Sonenberg N 1992 mRNAs containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing initiation factor elF-4E. EMBO J 11:4153-4158
47. Rousseau D, Gingras AC, Pause A, Sonenberg N 1996 The elF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13:2415-2420
48. Jiang H, Coleman J, Miskimins R, Miskimins WK 2003 Expression of constitutively active 4EBP-1 enhances p27Kipl expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int 3:2
49. Brunn GJ, Fadden P, Haystead TAJ, Lawrence Jr JC 1997 The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH-terminus. J Biol Chem 272:32547-32550
50. Hu C, Pang S, Kong X, Velleca M, Lawrence Jr JC 1994 Molecular cloning and tissue distribution of PHAS-I, an intracellular target for insulin and growth factors. Proc Natl Acad Sci USA 91:3730-3734
51. Fadden P, Haystead TAJ, Lawrence Jr JC 1997 Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. J Biol Chem 272:10240-10247
52. Sevetson BR, Kong X, Lawrence Jr JC 1993 Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 90:10305-10309
53. Ferguson G, Mothe-Satney I, Lawrence Jr JC 2003 Ser-64 and Ser-111 in PHAS-I are dispensable for insulin-stimulated dissociation from elF4E. J Biol Chem 278:47459-47465
54. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
55. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT 1995 Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270:815-822
56. Haystead TAJ, Haystead CMM, Hu C, Lin T-A, Lawrence Jr JC 1994 Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase. Identification of a site phosphorylated by MAP kinase in vitro and in response to insulin in adipocytes. J Biol Chem 269:23185-23191